Skip to content
Open in App
Braveheart Bio

Braveheart Bio

web2

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies...

Stage
Undisclosed
Funding
Undisclosed
Team
0
0.0Mission ScoreFixed 0-100 scale

About

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Expert Insight
Braveheart Bio profile.

Expert Coverage

No published expert evaluations are available for this project yet.

Biotechnology & Medical ResearchHealthcare
0team
0evaluations
0subscribers